Olema Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except for share and per share amounts)
| Three Months Ended September 30, · Nine Months Ended September 30, | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2025 · 2024 · 2025 · 2024 | ||||||||
| Operating expenses: | ||||||||
| Research and development¹ | $ | 39,951 | $ | 33,226 | $ | 114,477 | $ | 92,218 |
| General and administrative | 5,926 | 4,395 | 14,137 | 13,272 | ||||
| Total operating expenses | 45,877 | 37,621 | 128,614 | 105,490 | ||||
| Loss from operations | (45,877) | (37,621) | (128,614) | (105,490) | ||||
| Other income: | ||||||||
| Interest income | 3,648 | 2,928 | 12,214 | 9,388 | ||||
| Other income | 12 | 138 | 10 | 195 | ||||
| Total other income | 3,660 | 3,066 | 12,224 | 9,583 | ||||
| Net loss | $ | (42,217) | $ | (34,555) | $ | (116,390) | $ | (95,907) |
| Net loss per share, basic and diluted | $ | (0.49) | $ | (0.60) | $ | (1.36) | $ | (1.80) |
| Weighted average shares used to compute net loss per share, basic and diluted² | 85,732,221 | 57,262,803 | 85,553,078 | 53,194,081 | ||||
| ¹The amounts for the nine months ended September 30, 2025 and 2024 include one-time milestone payments to Aurigene of $10,000 and $5,000, respectively. | ||||||||
| ² For the three and nine months ended September 30, 2025, the weighted average shares used to compute net loss per share, basic and diluted, include the effect from the pre-funded warrants. | ||||||||
| Three Months Ended September 30, · Nine Months Ended September 30, | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2025 · 2024 · 2025 · 2024 | ||||||||
| Net loss | $ | (42,217) | $ | (34,555) | $ | (116,390) | $ | (95,907) |
| Other comprehensive gain: | ||||||||
| Net unrealized gain on marketable securities | 212 | 582 | 383 | 117 | ||||
| Total comprehensive loss | $ | (42,005) | $ | (33,973) | $ | (116,007) | $ | (95,790) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.